Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...

ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first ...

In the assessment of 12-month price targets, analysts unveil insights for Alkermes, presenting an average target of $37.14, a high estimate of $50.00, and a low estimate of $25.00. This current ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which ...

Below are the earnings highlights for Alkermes plc (ALKS): Earnings: $36.83 million in Q1 vs. -$41.85 million in the same period ...

DUBLIN — DUBLIN — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based company said it had ...

"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities acros ...

Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...

Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago. These figures are ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...